Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Milatuzumab||IMMU-115|hLL1||CD74 Antibody 3||Milatuzumab (IMMU-115) is a monocloncal antibody to CD74 that induces apoptosis and targets tumor cells with high CD74 expression, such as B-cells (PMID: 25754579, PMID: 28466956).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||chronic lymphocytic leukemia||not applicable||Milatuzumab||Phase Ib/II||Actionable||In a Phase Ib/II trial, Milatuzumab (hLL1) treatment of elderly and refractory chronic lymphocytic leukemia patients resulted in one patient (12.5%, 1/8) with an ongoing response at 18-months (PMID: 28466956).||28466956|
|Unknown unknown||hematologic cancer||no benefit||Milatuzumab||Phase I||Actionable||In a Phase I trial, Milatuzumab (hLL1) treatment of a mixed cohort of B-cell malignancies patients, resulted in stable disease in 35% (8/23), but there was no evidence of tumor shrinkage (PMID: 25754579).||25754579|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|